With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have ...

Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Insmed. According to TipRanks, Schwartz has an average return of 15.6% and a 47.59% success ...

Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...

Q2 2025 Management View William H. Lewis, President, CEO & Chairman, highlighted, "Insmed is now three for three, all three ...

In a report released today, Kelly Shi from Jefferies maintained a Buy rating on Insmed, with a price target of $129.00. The company’s shares closed today at $109.30. Elevate You ...

Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.